CoChat
Sign Up
Cited by 17Proteoglycans and glycosaminoglycans researchRenal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

The role of hyaluronan in renal cell carcinoma

Open access
Jin, Chenchen, Zong, Yunfeng·2023·Frontiers in Immunology
DOI 10.3389/fimmu.2023.1127828PMC PMC10019822
Open this paper in CoChat — free accountOpen PDF

Abstract

Renal cell carcinoma (RCC) is associated with high mortality rates worldwide and survival among RCC patients has not improved significantly in the past few years. A better understanding of the pathogenesis of RCC can enable the development of more effective therapeutic strategies against RCC. Hyaluronan (HA) is a glycosaminoglycan located in the extracellular matrix (ECM) that has several roles in biology, medicine, and physiological processes, such as tissue homeostasis and angiogenesis. Dysregulated HA and its receptors play important roles in fundamental cellular and molecular biology processes such as cell signaling, immune modulation, tumor progression and angiogenesis. There is emerging evidence that alterations in the production of HA regulate RCC development, thereby acting as important biomarkers as well as specific therapeutic targets. Therefore, targeting HA or combining it with other therapies are promising therapeutic strategies. In this Review, we summarize the available data on the role of abnormal regulation of HA and speculate on its potential as a therapeutic target against RCC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1127828

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Only low-molecular-weight HA fragments (<12 kDa) can pass the glomerular barrier; under normal physiology, only ~1-2% of HA is removed by the kidneys, limited to these small fragments.

    “Similarly, only low-molecular-weight HA fragments (<12 kDa) are able to pass the glomerular barrier—indeed, under normal physiology, only ~1–2% of HA is removed by the kidneys, limited to these small fragments [252].”

    From Biomaterials in Postoperative Adhesion Barriers and Uterine Tissue Engineering (2025) · cites this paper as [252]

  • The majority of high-molecular-weight HA produced in the body is captured and metabolized by the liver, with liver sinusoidal endothelium and Kupffer cells clearing most circulating HA each day.

    “Natural macromolecules illustrate this route: the majority of high-molecular-weight HA produced in the body is captured and metabolized by the liver, with the liver sinusoidal endothelium and Kupffer cells clearing most circulating HA each day [252].”

    From Biomaterials in Postoperative Adhesion Barriers and Uterine Tissue Engineering (2025) · cites this paper as [252]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 173

  1. [1]Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin (2021) 71: 209–49. doi: 10.3322/caac.21660 33538338 · DOI · Paper page
  2. [2]Hsieh JJ Purdue MP Signoretti S Swanton C Albiges L Schmidinger M. Renal cell carcinoma. Nat Rev Dis Primers (2017) 3: 17009. doi: 10.1038/nrdp.2017.9 28276433 PMC5936048 · DOI
  3. [3]Petejova N Martinek A. Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. BioMed Pap Med Fac Univ Palacky Olomouc Czech Repub (2016) 160: 183–94. doi: 10.5507/bp.2015.050 26558360 · DOI
  4. [4]Ricketts CJ De Cubas AA Fan H Smith CC Lang M Reznik E. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep (2018) 23: 313–26. doi: 10.1016/j.celrep.2018.03.075 PMC6075733 29617669 · DOI
  5. [5]Linehan WM Ricketts CJ. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol (2019) 16: 539–52. doi: 10.1038/s41585-019-0211-5 31278395 · DOI
  6. [6]Brian I Rini SCCB. Renal cell carcinoma. Lancet (2009) 373: 1119–32. doi: 10.1016/S0140-6736(09)60229-4 19269025 · DOI
  7. [7]Bjorge T Tretli S Engeland A. Relation of height and body mass index to renal cell carcinoma in two million norwegian men and women. Am J Epidemiol (2004) 160: 1168–76. doi: 10.1093/aje/kwh345 15583369 · DOI
  8. [8]van Dijk BAC Schouten LJ Kiemeney LALM Goldbohm RA van den Brandt PA. Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands cohort study. Am J Epidemiol (2004) 160: 1159–67. doi: 10.1093/aje/kwh344 15583368 · DOI
  9. [9]Hunt JD van der Hel OL McMillan GP Boffetta P Brennan P. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. Int J Cancer (2005) 114: 101–08. doi: 10.1002/ijc.20618 15523697 · DOI
  10. [10]Yuan JM Castelao JE Gago-Dominguez M Yu MC Ross RK. Tobacco use in relation to renal cell carcinoma. Cancer Epidemiol. Biomarkers Prev (1998) 7: 429–33. 9610793
  11. [11]McLaughlin JK Chow WH Mandel JS Mellemgaard A McCredie M Lindblad P. International renal-cell cancer study. VIII. Role diuretics other anti-hypertensive medications hypertension. Int J Cancer (1995) 63: 216–21. doi: 10.1002/ijc.2910630212 7591207 · DOI
  12. [12]Colt JS Schwartz K Graubard BI Davis F Ruterbusch J DiGaetano R. Hypertension and risk of renal cell carcinoma among white and black americans. Epidemiology (2011) 22: 797– 804. doi: 10.1097/EDE.0b013e3182300720 21881515 PMC3188386 · DOI
  13. [13]Gray RE Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician (2019) 99: 179–84. 30702258
  14. [14]Tostain J Li G Gentil-Perret A Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment. Eur J Cancer (2010) 46: 3141–48. doi: 10.1016/j.ejca.2010.07.020 20709527 · DOI
  15. [15]Li P Wong YN Armstrong K Haas N Subedi P Davis-Cerone M. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med (2016) 5: 169–81. doi: 10.1002/cam4.574 PMC4735783 26645975 · DOI
  16. [16]Posadas EM Limvorasak S Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol (2017) 13: 496– 511. doi: 10.1038/nrneph.2017.82 28691713 · DOI
  17. [17]Garantziotis S Savani RC. Hyaluronan biology: A complex balancing act of structure, function, location and context. Matrix Biol (2019) 78-79: 1– 10. doi: 10.1016/j.matbio.2019.02.002 30802498 PMC6774756 · DOI
  18. [18]Simpson MA de la Motte C Sherman LS Weigel PH. Advances in hyaluronan biology: signaling, regulation, and disease mechanisms. Int J Cell Biol (2015) 2015: 690572. doi: 10.1155/2015/690572 26446415 PMC4584047 · DOI
  19. [19]Cyphert JM Trempus CS Garantziotis S. Size matters: molecular weight specificity of hyaluronan effects in cell biology. Int J Cell Biol (2015) 2015: 1– 08. doi: 10.1155/2015/563818 PMC4581549 26448754 · DOI
  20. [20]Caon I Bartolini B Parnigoni A Caravà E Moretto P Viola M. Revisiting the hallmarks of cancer: The role of hyaluronan. Semin Cancer Biol (2020) 62: 9– 19. doi: 10.1016/j.semcancer.2019.07.007 31319162 · DOI
  21. [21]Sironen RK Tammi M Tammi R Auvinen PK Anttila M Kosma V. Hyaluronan in human malignancies. Exp Cell Res (2011) 317: 383–91. doi: 10.1016/j.yexcr.2010.11.017 21134368 · DOI
  22. [22]Kaul A Singampalli KL Parikh UM Yu L Keswani SG Wang X. Hyaluronan, a double-edged sword in kidney diseases. Pediatr Nephrol (2022) 37: 735–44. doi: 10.1007/s00467-021-05113-9 PMC8960635 34009465 · DOI
  23. [23]Jokelainen O Pasonen-Seppänen S Tammi M Mannermaa A Aaltomaa S Sironen R. Cellular hyaluronan is associated with a poor prognosis in renal cell carcinoma. Urol Oncol (2020) 38: 611–86. doi: 10.1016/j.urolonc.2020.03.029 32360171 · DOI
  24. [24]Meyer K Palmer JW. The polysaccharide of the vitreous humor. Urol Oncol (1934) 107: 629–34. doi: 10.1016/S0021-9258(18)75338-6 · DOI
  25. [25]Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 4: 528–39. doi: 10.1038/nrc1391 15229478 · DOI · Paper page
  26. [26]Stridh S Palm F Hansell P. Renal interstitial hyaluronan: functional aspects during normal and pathological conditions. Am J Physiol Regul Integr Comp Physiol (2012) 302: R1235–49. doi: 10.1152/ajpregu.00332.2011 22513743 · DOI
  27. [27]Spicer AP Seldin MF Olsen AS Brown N Wells DE Doggett NA. Chromosomal localization of the human and mouse hyaluronan synthase genes. Genomics (1997) 41: 493–97. doi: 10.1006/geno.1997.4696 9169154 · DOI
  28. [28]Tammi MI Day AJ Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem (2002) 277: 4581–84. doi: 10.1074/jbc.R100037200 11717316 · DOI
  29. [29]Petrey AC de la Motte CA. Hyaluronan, a crucial regulator of inflammation. Front Immunol (2014) 5: 101. doi: 10.3389/fimmu.2014.00101 24653726 PMC3949149 · DOI · Paper page
  30. [30]Volpi N Schiller J Stern R Soltés L. Role, metabolism, chemical modifications and applications of hyaluronan. Curr Med Chem (2009) 16: 1718. doi: 10.2174/092986709788186138 19442142 · DOI
  31. [31]Lepperdinger G Strobl B Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem (1998) 273: 22466–70. doi: 10.1074/jbc.273.35.22466 9712871 · DOI
  32. [32]Csoka AB Frost GI Stern R. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol (2001) 20: 499– 508. doi: 10.1016/S0945-053X(01)00172-X 11731267 · DOI
  33. [33]Cherr GN Meyers SA Yudin AI VandeVoort CA Myles DG Primakoff P. The PH-20 protein in cynomolgus macaque spermatozoa: identification of two different forms exhibiting hyaluronidase activity. Dev Biol (1996) 175: 142–53. doi: 10.1006/dbio.1996.0102 8608861 · DOI
  34. [34]Yamaguchi Y Yamamoto H Tobisawa Y Irie F. TMEM2: A missing link in hyaluronan catabolism identified? Matrix Biol (2019) 78-79: 139–46. doi: 10.1016/j.matbio.2018.03.020 PMC6314907 29601864 · DOI
  35. [35]Spataro S Guerra C Cavalli A Sgrignani J Sleeman J Poulain L. CEMIP (HYBID, KIAA1199): structure, function and expression in health and disease. FEBS J (2022) 1-17. doi: 10.1111/febs.16600 35997767 · DOI
  36. [36]Domanegg K Sleeman JP Schmaus A. CEMIP, a promising biomarker that promotes the progression and metastasis of colorectal and other types of cancer. Cancers (Basel) (2022) 14: 5093. doi: 10.3390/cancers14205093 36291875 PMC9600181 · DOI
  37. [37]Kotla NG Bonam SR Rasala S Wankar J Bohara RA Bayry J. Recent advances and prospects of hyaluronan as a multifunctional therapeutic system. J Control Release (2021) 336: 598– 620. doi: 10.1016/j.jconrel.2021.07.002 34237401 · DOI
  38. [38]Chanmee T Ontong P Itano N. Hyaluronan: A modulator of the tumor microenvironment. Cancer Lett (2016) 375: 20– 30. doi: 10.1016/j.canlet.2016.02.031 26921785 · DOI
  39. [39]Rilla K Oikari S Jokela TA Hyttinen JMT Kärnä R Tammi RH. Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3*. J Biol Chem (2013) 288: 5973–83. doi: 10.1074/jbc.M112.443879 PMC3581382 23303191 · DOI
  40. [40]Itano N Sawai T Yoshida M Lenas P Yamada Y Imagawa M. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem (1999) 274: 25085–92. doi: 10.1074/jbc.274.35.25085 10455188 · DOI · Paper page
  41. [41]Spicer AP Tien JL Joo A Bowling RJ. Investigation of hyaluronan function in the mouse through targeted mutagenesis. Glycoconj J (2002) 19: 341–45. doi: 10.1023/A:1025321105691 12975614 · DOI
  42. [42]Šoltés L Mendichi R Kogan G Schiller J Stankovská M Arnhold J. Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules (2006) 7: 659–68. doi: 10.1021/bm050867v 16529395 · DOI
  43. [43]Schmut O Ansari AN Faulborn J. Degradation of hyaluronate by the concerted action of ozone and sunlight. Ophthalmic Res (1994) 26: 340–43. doi: 10.1159/000267499 7715914 · DOI
  44. [44]Schiller S Dorfman A. The metabolism of mucopolysaccharides in animals: iv. the influence of insulin. J Biol Chem (1957) 227: 625–32. doi: 10.1016/S0021-9258(18)70742-4 13462984 · DOI
  45. [45]Fraser JR Laurent TC Pertoft H Baxter E. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J (1981) 200: 415–24. doi: 10.1042/bj2000415 PMC1163551 7340841 · DOI
  46. [46]Fraser JR Appelgren L Laurent T. Tissue uptake of circulating hyaluronic acid. Cell Tissue Res (1983) 233: 285–93. doi: 10.1007/BF00238296 6413068 · DOI
  47. [47]Laurent TC Lilja K Brunnberg L Engström-Laurent A Laurent UB Lindqvist U. Urinary excretion of hyaluronan in man. Scand J Clin Lab Invest (1987) 47: 793. doi: 10.1080/00365518709168948 3433001 · DOI
  48. [48]Beech DJ Madan AK Deng N. Expression of PH-20 in normal and neoplastic breast tissue. J Surg Res (2002) 103: 203–07. doi: 10.1006/jsre.2002.6351 11922735 · DOI
  49. [49]Madan AK Pang Y Wilkiemeyer MB Yu D Beech DJ. Increased hyaluronidase expression in more aggressive prostate adenocarcinoma. Oncol Rep (1999) 6: 1431. doi: 10.3892/or.6.6.1431 10523725 · DOI
  50. [50]Godin DA Fitzpatrick PC Scandurro AB Belafsky PC Woodworth BA Amedee RG. PH20: a novel tumor marker for laryngeal cancer. Arch Otolaryngol Head Neck Surg (2000) 126: 402–04. doi: 10.1001/archotol.126.3.402 10722016 · DOI
  51. [51]Yoshida H Okada Y. Role of HYBID (hyaluronan binding protein involved in hyaluronan depolymerization), alias KIAA1199/CEMIP, in hyaluronan degradation in normal and photoaged skin. Int J Mol Sci (2019) 20: 5804. doi: 10.3390/ijms20225804 31752258 PMC6888145 · DOI
  52. [52]Tobisawa Y Fujita N Yamamoto H Ohyama C Irie F Yamaguchi Y. The cell surface hyaluronidase TMEM2 is essential for systemic hyaluronan catabolism and turnover. J Biol Chem (2021) 297: 101281. doi: 10.1016/j.jbc.2021.101281 34624311 PMC8561002 · DOI
  53. [53]Wells AF Larsson E Tengblad A Fellström B Tufveson G Klareskog L. The localization of hyaluronan in normal and rejected human kidneys. Transplantation (1990) 50: 240–43. doi: 10.1097/00007890-199008000-00014 2382292 · DOI
  54. [54]Johnsson C Tufveson G Wahlberg J Hällgren R. Experimentally-induced warm renal ischemia induces cortical accumulation of hyaluronan in the kidney. Kidney Int (1996) 50: 1224–29. doi: 10.1038/ki.1996.431 8887281 · DOI
  55. [55]Hansell P Goransson V Odlind C Gerdin B Hallgren R. Hyaluronan content in the kidney in different states of body hydration. Kidney Int (2000) 58: 2061–68. doi: 10.1111/j.1523-1755.2000.00378.x 11044226 · DOI
  56. [56]Göransson V Johnsson C Nylander O Hansell P. Renomedullary and intestinal hyaluronan content during body water excess: a study in rats and gerbils. J Physiol (2002) 542: 315–22. doi: 10.1113/jphysiol.2001.014894 PMC2290385 12096072 · DOI
  57. [57]Pedagogos E Hewitson TD Nicholls KM Becker GJ. Hyaluronan and rat renal fibroblasts: in vitro studies. Nephron Clin Pract (2001) 88: 347–53. doi: 10.1159/000046019 11474230 · DOI
  58. [58]Rügheimer L Olerud J Johnsson C Takahashi T Shimizu K Hansell P. Hyaluronan synthases and hyaluronidases in the kidney during changes in hydration status. Matrix Biol (2009) 28: 390–95. doi: 10.1016/j.matbio.2009.07.002 19635555 · DOI
  59. [59]Stridh S Kerjaschki D Chen Y Rügheimer L Åstrand ABM Johnsson C. Angiotensin converting enzyme inhibition blocks interstitial hyaluronan dissipation in the neonatal rat kidney via hyaluronan synthase 2 and hyaluronidase 1. Matrix Biol (2011) 30: 62–9. doi: 10.1016/j.matbio.2010.09.006 20933085 · DOI
  60. [60]Colombaro V Jadot I Declèves A Voisin V Giordano L Habsch I. Hyaluronidase 1 and hyaluronidase 2 are required for renal hyaluronan turnover. Acta Histochem (2015) 117: 83– 91. doi: 10.1016/j.acthis.2014.11.007 25468725 · DOI
  61. [61]Decleves AE Caron N Voisin V Legrand A Bouby N Kultti A. Synthesis and fragmentation of hyaluronan in renal ischaemia. Nephrol Dial Transplant (2012) 27: 3771–81. doi: 10.1093/ndt/gfs098 22529164 · DOI
  62. [62]Akin D Ozmen S Yilmaz ME. Hyaluronic acid as a new biomarker to differentiate acute kidney injury from chronic kidney disease. Iran J Kidney Dis (2017) 11: 409–13. 29190600
  63. [63]Stenvinkel P Heimbürger O Wang T Lindholm B Bergström J Elinder C. High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis (1999) 34: 1083–88. doi: 10.1016/S0272-6386(99)70014-4 10585318 · DOI
  64. [64]Jones S Jones S Phillips AO. Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. Kidney Int (2001) 59: 1739–49. doi: 10.1046/j.1523-1755.2001.0590051739.x 11318944 · DOI
  65. [65]Johnsson C Hallgren R Wahlberg J Tufveson G. Renal accumulation and distribution of hyaluronan after ureteral obstruction. Scand J Urol Nephrol (1997) 31: 327–31. doi: 10.3109/00365599709030614 9290160 · DOI
  66. [66]Sano N Kitazawa K Sugisaki T. Localization and roles of CD44, hyaluronic acid and osteopontin in IgA nephropathy. Nephron Clin Pract (2001) 89: 416–21. doi: 10.1159/000046113 11721159 · DOI
  67. [67]Verkoelen CF. Crystal retention in renal stone disease: a crucial role for the glycosaminoglycan hyaluronan? J Am Soc Nephrol (2006) 17: 1673–87. doi: 10.1681/ASN.2006010088 16707562 · DOI
  68. [68]Göransson V Hansell P Moss S Alcorn D Johnsson C Hällgren R. Renomedullary interstitial cells in culture; the osmolality and oxygen tension influence the extracellular amounts of hyaluronan and cellular expression of CD44. Matrix Biol (2001) 20: 129–36. doi: 10.1016/S0945-053X(01)00129-9 11334714 · DOI
  69. [69]GINETZINSKY AG. Relationship between urinary hyaluronidase and diuresis. Nature (1961) 189: 235–37. doi: 10.1038/189235b0 13705483 · DOI
  70. [70]Ito T Williams JD Fraser D Phillips AO. Hyaluronan attenuates transforming growth factor-β1-mediated signaling in renal proximal tubular epithelial cells. Am J Pathol (2004) 164: 1979–88. doi: 10.1016/s0002-9440(10)63758-3 PMC1615759 15161634 · DOI
  71. [71]van den Berg BM Wang G Boels M Avramut MC Jansen E Sol W. Glomerular function and structural integrity depend on hyaluronan synthesis by glomerular endothelium. J Am Soc Nephrol (2019) 30: 1886–97. doi: 10.1681/ASN.2019020192 PMC6779367 31308073 · DOI
  72. [72]Hällgren R Gerdin B Tufveson G. Hyaluronic acid accumulation and redistribution in rejecting rat kidney graft. Relationship to Transplant edema. J Exp Med (1990) 171: 2063–76. doi: 10.1084/jem.171.6.2063 PMC2187954 2191073 · DOI
  73. [73]Quail DF Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 19: 1423–37. doi: 10.1038/nm.3394 PMC3954707 24202395 · DOI · Paper page
  74. [74]Lai Y Tang F Huang Y He C Chen C Zhao J. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy. J Cell Physiol (2021) 236: 1616–27. doi: 10.1002/jcp.29969 32783202 · DOI
  75. [75]Nabi S Kessler ER Bernard B Flaig TW Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000 Res (2018) 7: 307. doi: 10.12688/f1000research.13179.1 PMC5850086 29568504 · DOI
  76. [76]Nakano O Sato M Naito Y Suzuki K Orikasa S Aizawa M. Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res (2001) 61: 5132–36. 11431351
  77. [77]Díaz-Montero CM Rini BI Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol (2020) 16: 721–35. doi: 10.1038/s41581-020-0316-3 32733094 · DOI
  78. [78]Stewart BJ Ferdinand JR Clatworthy MR. Using single-cell technologies to map the human immune system - implications for nephrology. Nat Rev Nephrol (2020) 16: 112–28. doi: 10.1038/s41581-019-0227-3 31831877 · DOI
  79. [79]Mier JW. The tumor microenvironment in renal cell cancer. Curr Opin Oncol (2019) 31: 194–99. doi: 10.1097/CCO.0000000000000512 PMC6467495 30985497 · DOI
  80. [80]Heidegger I Pircher A Pichler R. Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol (2019) 9: 490. doi: 10.3389/fonc.2019.00490 31259150 PMC6587703 · DOI · Paper page
  81. [81]Vuong L Kotecha RR Voss MH Hakimi AA. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discovery (2019) 9: 1349–57. doi: 10.1158/2159-8290.CD-19-0499 PMC6774890 31527133 · DOI
  82. [82]Cox TR. The matrix in cancer. Nat Rev Cancer (2021) 21: 217–38. doi: 10.1038/s41568-020-00329-7 33589810 · DOI
  83. [83]Lohi J Leivo I Oivula J Lehto VP Virtanen I. Extracellular matrix in renal cell carcinomas. Histol Histopathol (1998) 13: 785–96. doi: 10.14670/HH-13.785 9690136 · DOI
  84. [84]Moran H Cancel LM Huang P Roberge S Xu T Tarbell JM. Glycocalyx mechanotransduction mechanisms are involved in renal cancer metastasis. Matrix Biol Plus (2022) 13: 100100. doi: 10.1016/j.mbplus.2021.100100 35106474 PMC8789524 · DOI
  85. [85]Oxburgh L. The extracellular matrix environment of clear cell renal cell carcinoma. Cancers (Basel) (2022) 14: 4072. doi: 10.3390/cancers14174072 36077607 PMC9454539 · DOI
  86. [86]Gatto F Dabestani S Bratulic S Limeta A Maccari F Galeotti F. Plasma and urine free glycosaminoglycans as monitoring biomarkers in nonmetastatic renal cell carcinoma–a prospective cohort study. Eur Urol Open Sci (2022) 42: 30–9. doi: 10.1016/j.euros.2022.06.003 PMC9334826 35911082 · DOI
  87. [87]Ucakturk E Akman O Sun X Baydar DE Dolgun A Zhang F. Changes in composition and sulfation patterns of glycoaminoglycans in renal cell carcinoma. Glycoconj J (2016) 33: 103–12. doi: 10.1007/s10719-015-9643-1 26662466 · DOI
  88. [88]Tavianatou AG Caon I Franchi M Piperigkou Z Galesso D Karamanos NK. Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer. FEBS J (2019) 286: 2883–908. doi: 10.1111/febs.14777 30724463 · DOI
  89. [89]Price Z Lokman N Ricciardelli C. Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers (Basel) (2018) 10: 482. doi: 10.3390/cancers10120482 30513961 PMC6316154 · DOI
  90. [90]Weigel PH Baggenstoss BA. What is special about 200 kDa hyaluronan that activates hyaluronan receptor signaling? Glycobiology (2017) 27: 868–77. doi: 10.1093/glycob/cwx039 PMC5881711 28486620 · DOI
  91. [91]Lee-Sayer SSM Dong Y Arif AA Olsson M Brown KL Johnson P. The where, when, how, and why of hyaluronan binding by immune cells. Front Immunol (2015) 6: 150. doi: 10.3389/fimmu.2015.00150 25926830 PMC4396519 · DOI
  92. [92]Schwertfeger KL Cowman MK Telmer PG Turley EA McCarthy JB. Hyaluronan, inflammation, and breast cancer progression. Front Immunol (2015) 6: 236. doi: 10.3389/fimmu.2015.00236 26106384 PMC4459097 · DOI
  93. [93]Spinelli FM Vitale DL Demarchi G Cristina C Alaniz L. The immunological effect of hyaluronan in tumor angiogenesis. Clin Transl Immunol (2015) 4: e52. doi: 10.1038/cti.2015.35 PMC4685440 26719798 · DOI
  94. [94]Kobayashi N Miyoshi S Mikami T Koyama H Kitazawa M Takeoka M. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res (2010) 70: 7073–83. doi: 10.1158/0008-5472.CAN-09-4687 20823158 · DOI
  95. [95]Evanko SP Potter-Perigo S Bollyky PL Nepom GT Wight TN. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol (2012) 31: 90– 100. doi: 10.1016/j.matbio.2011.10.004 22155153 PMC3288568 · DOI
  96. [96]Ruffell B Johnson P. Hyaluronan induces cell death in activated T cells through CD44. J Immunol (2008) 181: 7044–54. doi: 10.4049/jimmunol.181.10.7044 18981124 · DOI
  97. [97]Matsumoto G Nghiem MP Nozaki N Schmits R Penninger JM. Cooperation between CD44 and LFA-1/CD11a adhesion receptors in lymphokine-activated killer cell cytotoxicity. J Immunol (1998) 160: 5781–89. doi: 10.4049/jimmunol.160.12.5781 9637488 · DOI
  98. [98]de la Torre M Wells AF Bergh J Lindgren A. Localization of hyaluronan in normal breast tissue, radial scar, and tubular breast carcinoma. Hum Pathol (1993) 24: 1294–97. doi: 10.1016/0046-8177(93)90262-f 8276376 · DOI
  99. [99]Wang SJ Bourguignon LYW. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol (2011) 178: 956–63. doi: 10.1016/j.ajpath.2010.11.077 PMC3069910 21356346 · DOI
  100. [100]Hasselbalch H Hovgaard D Nissen N Junker P. Serum hyaluronan is increased in malignant lymphoma. Am J Hematol (1995) 50: 231–33. doi: 10.1002/ajh.2830500402 7485095 · DOI
  101. [101]Park JB Kwak H Lee S. Role of hyaluronan in glioma invasion. Cell Adh Migr (2008) 2: 202–07. doi: 10.4161/cam.2.3.6320 PMC2634087 19262113 · DOI
  102. [102]Takabe P Siiskonen H Rönkä A Kainulainen K Pasonen-Seppänen S. The impact of hyaluronan on tumor progression in cutaneous melanoma. Front Oncol (2022) 11: 811434. doi: 10.3389/fonc.2021.811434 35127523 PMC8813769 · DOI
  103. [103]Pirinen RT Tammi RH Tammi MI Paakko PK Parkkinen JJ Agren UM. Expression of hyaluronan in normal and dysplastic bronchial epithelium and in squamous cell carcinoma of the lung. Int J Cancer (1998) 79: 251–55. doi: 10.1002/(sici)1097-0215(19980619)79:3<251::aid-ijc7>3.0.co;2-o 9645346 · DOI
  104. [104]Li JH Wang YC Qin CD Yao RR Zhang R Wang Y. Over expression of hyaluronan promotes progression of HCC via CD44-mediated pyruvate kinase M2 nuclear translocation. Am J Cancer Res (2016) 6: 509–21. PMC4859677 27186420
  105. [105]Zoltan-Jones A Huang L Ghatak S Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem (2003) 278: 45801–10. doi: 10.1074/jbc.M308168200 12954618 · DOI
  106. [106]Rilla K Pasonen-Seppänen S Kärnä R Karjalainen HM Törrönen K Koistinen V. HAS3-induced accumulation of hyaluronan in 3D MDCK cultures results in mitotic spindle misorientation and disturbed organization of epithelium. Histochem Cell Biol (2012) 137: 153–64. doi: 10.1007/s00418-011-0896-x 22159845 · DOI
  107. [107]Sun M Guo S Yao J Xiao Y Sun R Ma W. MicroRNA-125a suppresses cell migration, invasion, and regulates hyaluronic acid synthase 1 expression by targeting signal transducers and activators of transcription 3 in renal cell carcinoma cells. J Cell Biochem (2019) 120: 1894–902. doi: 10.1002/jcb.27503 30187954 · DOI
  108. [108]Chi A Shirodkar SP Escudero DO Ekwenna OO Yates TJ Ayyathurai R. Molecular characterization of kidney cancer. Cancer (2012) 118: 2394–402. doi: 10.1002/cncr.26520 PMC3232339 21887686 · DOI
  109. [109]Cai JL Li M Na YQ. Correlation between hyaluronic acid, hyaluronic acid synthase and human renal clear cell carcinoma. Chin J Cancer Res (2011) 23: 59– 63. doi: 10.1007/s11670-011-0059-6 23467480 PMC3587526 · DOI
  110. [110]Kusmartsev S Kwenda E Dominguez-Gutierrez PR Crispen PL O’Malley P. High levels of PD-L1+ and HYAL2+ myeloid-derived suppressor cells in renal cell carcinoma. J Kidney Cancer Vhl (2022) 9: 1– 06. doi: 10.15586/jkcvhl.v9i2.208 PMC9021011 35528727 · DOI
  111. [111]Dominguez-Gutierrez PR Kwenda EP Donelan W O’Malley P Crispen PL Kusmartsev S. HYAL2 expression in tumor-associated myeloid cells mediates cancer-related inflammation in bladder cancer. Cancer Res (2021) 81: 648–57. doi: 10.1158/0008-5472.CAN-20-1144 33239427 · DOI
  112. [112]Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer (2011) 11: 254–67. doi: 10.1038/nrc3023 21390059 · DOI
  113. [113]Shigeishi H Higashikawa K Takechi M. Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers. J Cancer Res Clin Oncol (2014) 140: 1629–40. doi: 10.1007/s00432-014-1653-z PMC11823788 24676428 · DOI
  114. [114]Jiang D Liang J Fan J Yu S Chen S Luo Y. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med (2005) 11: 1173–79. doi: 10.1038/nm1315 16244651 · DOI · Paper page
  115. [115]Lundy J Gearing LJ Gao H West AC McLeod L Deswaerte V. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Oncogene (2021) 40: 6007–22. doi: 10.1038/s41388-021-01992-2 34400766 · DOI
  116. [116]Dang S Peng Y Ye L Wang Y Qian Z Chen Y. Stimulation of TLR4 by LMW-HA induces metastasis in human papillary thyroid carcinoma through CXCR7. Clin Dev Immunol (2013) 2013: 1– 11. doi: 10.1155/2013/712561 PMC3865734 24363762 · DOI
  117. [117]McCourt PA Ek B Forsberg N Gustafson S. Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J Biol Chem (1994) 269: 30081–84. doi: 10.1016/S0021-9258(18)43775-1 7527024 · DOI
  118. [118]Jackson DG. Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking. Matrix Biol (2019) 78-79: 219–35. doi: 10.1016/j.matbio.2018.02.001 29425695 · DOI
  119. [119]Jackson DG Prevo R Clasper S Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol (2001) 22: 317–21. doi: 10.1016/S1471-4906(01)01936-6 11377291 · DOI
  120. [120]Harris EN Baker E. Role of the hyaluronan receptor, stabilin-2/HARE, in health and disease. Int J Mol Sci (2020) 21: 3504. doi: 10.3390/ijms21103504 32429122 PMC7279005 · DOI
  121. [121]Zheng C Zheng L Yoo J Guo H Zhang Y Guo X. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell (2017) 169: 1342–56. doi: 10.1016/j.cell.2017.05.035 28622514 · DOI · Paper page
  122. [122]Day AJ Milner CM. TSG-6: A multifunctional protein with anti-inflammatory and tissue-protective properties. Matrix Biol (2019) 78-79: 60– 83. doi: 10.1016/j.matbio.2018.01.011 29362135 · DOI · Paper page
  123. [123]Liu B Liu T Liu Y Feng X Jiang X Long J. TSG-6 promotes cancer cell aggressiveness in a CD44-dependent manner and reprograms normal fibroblasts to create a pro-metastatic microenvironment in colorectal cancer. Int J Biol Sci (2022) 18: 1677–94. doi: 10.7150/ijbs.69178 PMC8898369 35280699 · DOI
  124. [124]Zhuo L Hascall VC Kimata K. Inter-α-trypsin inhibitor, a covalent protein-glycosaminoglycan-protein complex. J Biol Chem (2004) 279: 38079–82. doi: 10.1074/jbc.R300039200 15151994 · DOI
  125. [125]Obayashi Y Yabushita H Kanyama K Noguchi M Zhuo L Kimata K. Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer. Oncol Rep (2008) 19: 1245. doi: 10.3892/or.19.5.1245 18425383 · DOI
  126. [126]Zhang M Li N Liang Y Liu J Zhou Y Liu C. Hyaluronic acid binding protein 1 overexpression is an indicator for disease-free survival in cervical cancer. Int J Clin Oncol (2017) 22: 347–52. doi: 10.1007/s10147-016-1077-7 28039537 · DOI
  127. [128]Varga I Hutóczki G Szemcsák CD Zahuczky G Tóth J Adamecz Z. Brevican, neurocan, tenascin-c and versican are mainly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res (2012) 18: 413–20. doi: 10.1007/s12253-011-9461-0 21997179 · DOI
  128. [129]Day AJ Prestwich GD. Hyaluronan-binding proteins: Tying up the giant. J Biol Chem (2002) 277: 4585–88. doi: 10.1074/jbc.R100036200 11717315 · DOI · Paper page
  129. [130]Milner CM Day AJ. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci (2003) 116: 1863–73. doi: 10.1242/jcs.00407 12692188 · DOI
  130. [131]Ponta H Sherman L Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol (2003) 4: 33– 45. doi: 10.1038/nrm1004 12511867 · DOI
  131. [132]Bono P Rubin K Higgins JM Hynes RO Brugge JS. Layilin, a novel integral membrane protein, is a hyaluronan receptor. Mol Biol Cell (2001) 12: 891– 900. doi: 10.1091/mbc.12.4.891 11294894 PMC32274 · DOI
  132. [133]Bourguignon LYW Wong G Earle CA Xia W. Interaction of low molecular weight hyaluronan with CD44 and toll-like receptors promotes the actin filament-associated protein 110-actin binding and MyD88-NFκB signaling leading to proinflammatory cytokine/chemokine production and breast tumor invasion. Cytoskeleton (Hoboken) (2011) 68: 671–93. doi: 10.1002/cm.20544 PMC3240717 22031535 · DOI
  133. [134]Karousou E Misra S Ghatak S Dobra K Götte M Vigetti D. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol (2017) 59: 3– 22. doi: 10.1016/j.matbio.2016.10.001 27746219 · DOI
  134. [135]Zhang H Li L Wang D. Increased expression of HMMR in renal cell carcinoma is an independent prognostic factor. Oncol Lett (2023) 25: 28. doi: 10.3892/ol.2022.13614 36478897 PMC9713828 · DOI
  135. [136]Ding Y Xiong S Chen X Pan Q Fan J Guo J. HAPLN3 inhibits apoptosis and promotes EMT of clear cell renal cell carcinoma via ERK and bcl-2 signal pathways. J Cancer Res Clin Oncol (2022) 149: 79– 90. doi: 10.1007/s00432-022-04421-3 36374334 PMC11796846 · DOI
  136. [137]Borowsky ML Hynes RO. Layilin, a novel talin-binding transmembrane protein homologous with c-type lectins, is localized in membrane ruffles. J Cell Biol (1998) 143: 429–42. doi: 10.1083/jcb.143.2.429 PMC2132847 9786953 · DOI
  137. [138]Mahuron KM Moreau JM Glasgow JE Boda DP Pauli ML Gouirand V. Layilin augments integrin activation to promote antitumor immunity. J Exp Med (2020) 217: e20192080. doi: 10.1084/jem.20192080 32539073 PMC7478725 · DOI
  138. [139]Adachi T Arito M Suematsu N Kamijo-Ikemori A Omoteyama K Sato T. Roles of layilin in TNF-α-induced epithelial-mesenchymal transformation of renal tubular epithelial cells. Biochem Biophys Res Commun (2015) 467: 63–9. doi: 10.1016/j.bbrc.2015.09.121 26410531 · DOI
  139. [140]Falkowski M Schledzewski K Hansen B Goerdt S. Expression of stabilin-2, a novel fasciclin-like hyaluronan receptor protein, in murine sinusoidal endothelia, avascular tissues, and at solid/liquid interfaces. Histochem Cell Biol (2003) 120: 361–69. doi: 10.1007/s00418-003-0585-5 14598175 · DOI
  140. [141]Banerji S Ni J Wang SX Clasper S Su J Tammi R. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol (1999) 144: 789– 801. doi: 10.1083/jcb.144.4.789 10037799 PMC2132933 · DOI
  141. [142]Han DH Song HK Lee SY Song J Piao SG Yoon HE. Upregulation of hyaluronan and its binding receptors in an experimental model of chronic cyclosporine nephropathy. Nephrol (Carlton) (2010) 15: 216–24. doi: 10.1111/j.1440-1797.2009.01167.x 20470282 · DOI
  142. [143]Karinen S Hujanen R Salo T Salem A. The prognostic influence of lymphatic endothelium–specific hyaluronan receptor 1 in cancer: A systematic review. Cancer Sci (2022) 113: 17– 27. doi: 10.1111/cas.15199 34775672 PMC8748220 · DOI
  143. [144]Jacobetz MA Chan DS Neesse A Bapiro TE Cook N Frese KK. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 62: 112–20. doi: 10.1136/gutjnl-2012-302529 PMC3551211 22466618 · DOI · Paper page
  144. [145]Shepard HM. Breaching the castle walls: Hyaluronan depletion as a therapeutic approach to cancer therapy. Front Oncol (2015) 5: 192. doi: 10.3389/fonc.2015.00192 26380222 PMC4551830 · DOI
  145. [146]Jiang D Liang J Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 91: 221–64. doi: 10.1152/physrev.00052.2009 PMC3051404 21248167 · DOI · Paper page
  146. [147]Heldin P Asplund T Teder P Suzuki M Vrochides D Papanikolaou V. Regulation of hyaluronan synthesis and the interaction of hyaluronan with cells. Acta Orthopaedica Scandinavica (2009) 66: 160–62. doi: 10.3109/17453679509157682 · DOI
  147. [148]McBride WH Bard JB. Hyaluronidase-sensitive halos around adherent cells. their role in blocking lymphocyte-mediated cytolysis. J Exp Med (1979) 149: 507–15. doi: 10.1084/jem.149.2.507 PMC2184811 762499 · DOI
  148. [149]Rilla K Siiskonen H Tammi M Tammi R. Hyaluronan coated extracellular vesicles a novel link between hyaluronan and cancer. Adv Cancer Res (2014) 123: 121–48. doi: 10.1016/B978-0-12-800092-2.00005-8 25081528 · DOI
  149. [150]Lokeshwar VB Summan M Andre J. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res (2014) 123: 35– 65. doi: 10.1016/B978-0-12-800092-2.00002-2 25081525 PMC4791948 · DOI
  150. [151]Golshani R Lopez L Estrella V Kramer M Iida N Lokeshwar VB. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res (2008) 68: 483–91. doi: 10.1158/0008-5472.CAN-07-2140 18199543 · DOI
  151. [152]Michl P Gress TM. Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid. Gut (2012) 61: 1377–79. doi: 10.1136/gutjnl-2012-302604 22661496 · DOI
  152. [153]Urakawa H Nishida Y Wasa J Arai E Zhuo L Kimata K. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer (2012) 130: 454–66. doi: 10.1002/ijc.26014 21387290 · DOI
  153. [154]Twarock S Freudenberger T Poscher E Dai G Jannasch K Dullin C. Inhibition of oesophageal squamous cell carcinoma progression by in vivo targeting of hyaluronan synthesis. Mol Cancer (2011) 10: 30. doi: 10.1186/1476-4598-10-30 21429221 PMC3078897 · DOI
  154. [155]Bhattacharyya SS Paul S Mandal SK Banerjee A Boujedaini N Khuda-Bukhsh AR. A synthetic coumarin (4-Methyl-7 hydroxy coumarin) has anti-cancer potentials against DMBA-induced skin cancer in mice. Eur J Pharmacol (2009) 614: 128–36. doi: 10.1016/j.ejphar.2009.04.015 19393233 · DOI
  155. [156]Hiraga T Ito S Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res (2013) 73: 4112–22. doi: 10.1158/0008-5472.CAN-12-3801 23633482 · DOI
  156. [157]Uchakina ON Ban H McKallip RJ. Targeting hyaluronic acid production for the treatment of leukemia: Treatment with 4-methylumbelliferone leads to induction of MAPK-mediated apoptosis in K562 leukemia. Leuk Res (2013) 37: 1294–301. doi: 10.1016/j.leukres.2013.07.009 23876826 · DOI
  157. [158]Tamura R Yokoyama Y Yoshida H Imaizumi T Mizunuma H. 4-methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression. J Ovarian Res (2014) 7: 94. doi: 10.1186/s13048-014-0094-2 25304388 PMC4198731 · DOI
  158. [159]Lokeshwar VB Lopez LE Munoz D Chi A Shirodkar SP Lokeshwar SD. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res (2010) 70: 2613–23. doi: 10.1158/0008-5472.CAN-09-3185 PMC2848908 20332231 · DOI
  159. [160]Piccioni F Malvicini M Garcia MG Rodriguez A Atorrasagasti C Kippes N. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology (2012) 22: 400–10. doi: 10.1093/glycob/cwr158 22038477 · DOI
  160. [161]Twarock S Tammi MI Savani RC Fischer JW. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem (2010) 285: 23276–84. doi: 10.1074/jbc.M109.093146 PMC2906320 20463012 · DOI
  161. [162]Benitez A Yates TJ Lopez LE Cerwinka WH Bakkar A Lokeshwar VB. Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res (2011) 71: 4085–95. doi: 10.1158/0008-5472.CAN-10-4610 PMC3117105 21555367 · DOI
  162. [163]Koutsakis C Tavianatou A Kokoretsis D Baroutas G Karamanos NK. Sulfated hyaluronan modulates the functional properties and matrix effectors expression of breast cancer cells with different estrogen receptor status. Biomolecules (2021) 11: 1916. doi: 10.3390/biom11121916 34944559 PMC8699821 · DOI
  163. [164]Sato N Kohi S Hirata K Goggins M. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Cancer Sci (2016) 107: 569–75. doi: 10.1111/cas.12913 PMC4970823 26918382 · DOI
  164. [165]Morosi L Meroni M Ubezio P Fuso Nerini I Minoli L Porcu L. PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. J Exp Clin Cancer Res (2021) 40: 286. doi: 10.1186/s13046-021-02070-x 34507591 PMC8434701 · DOI
  165. [166]Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res (2009) 15: 7462–68. doi: 10.1158/1078-0432.CCR-09-0479 PMC2796593 20008845 · DOI
  166. [167]Weng X Maxwell-Warburton S Hasib A Ma L Kang L. The membrane receptor CD44: Novel insights into metabolism. Trends Endocrinol Metab (2022) 33: 318–32. doi: 10.1016/j.tem.2022.02.002 35249813 · DOI · Paper page
  167. [168]Hirose Y Saijou E Sugano Y Takeshita F Nishimura S Nonaka H. Inhibition of stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. Pro Natl Acad Sci USA (2012) 109: 4263–68. doi: 10.1073/pnas.1117560109 PMC3306694 22371575 · DOI
  168. [169]Gahan J Benitez A Yates T Chi A Miami F Bird V. Targeting RHAMM, a metastasis predictor, for kidney cancer therapy. J Urol (2011) 185: e156. doi: 10.1016/j.juro.2011.02.474 · DOI
  169. [170]Benitez A Yates T Chi A Gahan J Bird V Lokeshwar V. RHAMM- a potential predictor of metastasis and therapeutic target in kidney cancer. Cancer Res (2011) 71: 2598. doi: 10.1158/1538-7445.AM2011-2598 · DOI
  170. [171]Wang J Jordan AR Zhu H Hasanali SL Thomas E Lokeshwar SD. Targeting hyaluronic acid synthase-3 (HAS3) for the treatment of advanced renal cell carcinoma. Cancer Cell Int (2022) 22: 421. doi: 10.1186/s12935-022-02818-1 36581895 PMC9801563 · DOI
  171. [172]Liu HN Guo NN Guo WW Huang-Fu MY Vakili MR Chen JJ. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer. Acta Pharmacol Sin (2018) 39: 1681–92. doi: 10.1038/aps.2018.9 PMC6289358 29849132 · DOI
  172. [173]Lu H Zhao H Wang K Lv L. Novel hyaluronic acid–chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis. Int J Pharm (2011) 420: 358–65. doi: 10.1016/j.ijpharm.2011.08.046 21911044 · DOI
  173. [174]Nikitovic D Kouvidi K Kavasi R Berdiaki A Tzanakakis GN. Hyaluronan/hyaladherins - a promising axis for targeted drug delivery in cancer. Curr Drug Delivery (2016) 13: 500. doi: 10.2174/1567201813666151109103013 26549038 · DOI

Cited by

Sorted by citations

Authors
Jin, C., & Zong, Y.
Affiliations
Zhejiang Cancer Hospital (CN)
Corresponding author
Zong, Yunfeng
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2023-03-02
Volume
14
Pages
1127828-1127828
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2023.1127828
PMC
PMC10019822
OpenAlex
W4322773788
Cited by
17
References
1
Citations by year
2026: 1 · 2025: 5 · 2024: 10 · 2023: 1
FWCI
0.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
hyaluronic acid, renal cell carcinoma, extracellular matrix, hyaluronan receptor, tumor progression, angiogenesis, biomarkers, therapeutic target, glycosaminoglycans
MeSH terms
Carcinoma, Renal Cell, Extracellular Matrix, Humans, Hyaluronic Acid, Kidney Neoplasms, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review